Home Ingredients DermaNiA® (Niacinamide for Skin Health — Sabinsa)
Hair, Skin & Nails

DermaNiA® (Niacinamide for Skin Health — Sabinsa)

Evidence Level
Strong
2 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

DermaNiA® is Sabinsa's branded niacinamide (nicotinamide, vitamin B3) for skin health applications. Niacinamide has substantial published evidence for skin applications, primarily via topical use — multiple RCTs document improvements in hyperpigmentation, fine lines, wrinkles, skin barrier function, sebum production, and acne when applied at 2-5% topical concentrations. Oral niacinamide for skin has more limited but notable evidence: the landmark Chen 2015 trial (n=386, 1 year, NEJM) showed 500 mg twice daily reduced new non-melanoma skin cancer (NMSC) incidence by 23% in high-risk patients with prior NMSC history. The clinical oral dose for NMSC prevention is 500 mg twice daily; lower doses (100-500 mg/day) are common in skin-health supplements. Honest framing: oral niacinamide for general skin appearance (anti-aging, hyperpigmentation) has less robust evidence than topical niacinamide — for those endpoints, topical application is the better-evidenced delivery route. Oral niacinamide's most validated indication is NMSC chemoprevention in high-risk patients.

Studied Dose NMSC prevention (oral): 500 mg twice daily (1,000 mg/day total) — the Chen 2015 ONTRAC trial protocol. General skin support (oral): 100-500 mg/day. Topical niacinamide: 2-5% concentrations in creams/serums (the more robust evidence base for general skin appearance endpoints). Niacinamide is well-tolerated up to 3,000 mg/day in oral pharmaceutical use (e.g., bullous pemphigoid).
Active Compound Niacinamide (nicotinamide), the amide form of vitamin B3 — distinct from niacin (nicotinic acid) which causes flushing. Niacinamide is a precursor to NAD+ and NADP+, essential cellular coenzymes for redox reactions, DNA repair, and energy metabolism. Sabinsa's DermaNiA® specification not publicly detailed beyond marketing positioning as a high-purity niacinamide for skin applications.

Benefits

Non-melanoma skin cancer prevention — Chen 2015

ONTRAC trial (NEJM): 386 patients with history of NMSC randomized to oral niacinamide 500 mg twice daily vs placebo for 12 months. Outcome: 23% reduction in new NMSC incidence (basal cell + squamous cell carcinomas), 20% reduction in actinic keratoses. Strongest oral niacinamide evidence; standard of care for high-risk NMSC patients in dermatology guidelines. Effect disappears within 6 months of discontinuation.

Supported by Trial 1

Hyperpigmentation reduction (topical)

Multiple RCTs document 2-5% topical niacinamide significantly reduces facial hyperpigmented spots vs vehicle control. Mechanism: inhibits melanosome transfer from melanocytes to keratinocytes. Effect is dose-dependent and reversible. Evidence stronger than for oral niacinamide for this endpoint.

Supported by Trial 2

Skin barrier function improvement (topical)

Topical niacinamide upregulates ceramide, free fatty acid, and cholesterol synthesis in keratinocytes — improving skin barrier integrity. Documented in RCTs as reduced transepidermal water loss and improved skin hydration. Particularly relevant for sensitive skin and post-inflammatory barrier compromise.

Supported by Trial 2

Anti-aging skin improvements (topical)

Bissett 2005 8-week RCT (Olay-funded but methodologically sound): 5% topical niacinamide vs vehicle control improved fine lines/wrinkles, hyperpigmented spots, texture, red blotchiness, and sallowness vs control. Mechanism: NAD+ restoration in aging skin where NAD+ levels decline.

Supported by Trial 2

Acne treatment (topical and oral)

Topical 4% niacinamide has shown efficacy comparable to clindamycin in moderate inflammatory acne. Mechanism: anti-inflammatory, sebum-reducing, antimicrobial properties without antibiotic resistance concerns. Oral niacinamide also has acne evidence at 500-750 mg/day, often in multi-ingredient formulations.

Supported by Trial 2, Trial 1

NAD+ precursor pathway

Niacinamide is converted to NAD+ (nicotinamide adenine dinucleotide), the key cellular coenzyme for redox reactions, DNA repair (via PARP enzymes), and energy metabolism. NAD+ levels decline with age; skin NAD+ specifically decreases with UV exposure and oxidative stress. Restoring NAD+ via niacinamide supports broader cellular maintenance.

Supported by Trial 1

Mechanism of action

1

NAD+ pool restoration

Niacinamide is the most direct precursor to NAD+ via the salvage pathway, bypassing the slower de novo synthesis from tryptophan. Increased NAD+ supports mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin activity. Distinct from precursors like NR (nicotinamide riboside) which feed the same pathway via a different entry point.

2

Melanosome transfer inhibition (topical)

Niacinamide inhibits the transfer of mature melanosomes from melanocytes to surrounding keratinocytes — the rate-limiting step in skin pigmentation. Distinct from tyrosinase inhibition (hydroquinone, kojic acid) which prevents melanin synthesis. Both mechanisms can reduce hyperpigmentation, but niacinamide's approach is gentler and has lower irritation profile.

3

Anti-inflammatory and immunomodulatory effects

Niacinamide inhibits poly(ADP-ribose) polymerase (PARP) hyperactivation in UV-damaged cells, reducing inflammatory cytokine release. Also suppresses neutrophil chemotaxis and Th17 inflammatory responses — relevant to acne, rosacea, and inflammatory dermatoses.

4

Photoimmunoprotection (NMSC prevention)

Oral niacinamide preserves cellular ATP after UV exposure, reduces UV-induced immunosuppression, and enhances DNA repair via PARP energy preservation. These mechanisms collectively reduce UV-mutagenesis and explain the Chen 2015 NMSC chemoprevention effect.

Clinical trials

1
ONTRAC Trial: Oral Niacinamide for NMSC Prevention

Phase 3 randomized double-blind placebo-controlled trial in 386 patients with ≥2 NMSCs in the previous 5 years. Intervention: niacinamide 500 mg twice daily or placebo for 12 months.

386 patients with ≥2 NMSCs

Phase 3 randomized double-blind placebo-controlled trial in 386 patients with ≥2 NMSCs in the previous 5 years. Intervention: niacinamide 500 mg twice daily or placebo for 12 months. Outcome: 23% reduction in new NMSC incidence (P=0.02) — primary endpoint. 13% reduction in basal cell carcinomas, 30% reduction in squamous cell carcinomas. 20% reduction in actinic keratoses. Effect disappeared within 6 months of discontinuation. Published in NEJM 2015; incorporated into dermatology clinical practice for high-NMSC-risk patients.

2
Topical Niacinamide for Hyperpigmentation

Left-right randomized vehicle-controlled split-face trial in 79 Japanese women with multiple types of brown hyperpigmentation.

79 Japanese women with multiple types of brown hyperpigmentation

Left-right randomized vehicle-controlled split-face trial in 79 Japanese women with multiple types of brown hyperpigmentation. Topical niacinamide-containing product at 2% and 5% niacinamide significantly reduced facial hyperpigmented spots in dose-dependent manner. Effect reversed within 8 weeks of discontinuation. Foundational evidence for topical niacinamide in hyperpigmentation. Published in Journal of the American Academy of Dermatology.

Side effects and drug interactions

Common Potential side effects

Excellent tolerability profile at oral doses up to 1,000 mg/day.
Does not cause flushing (unlike niacin/nicotinic acid). This is a key distinguishing feature.
Possible mild GI effects at higher doses (>3,000 mg/day).
Rare hepatotoxicity reported at very high chronic doses (>3 g/day).
Topical niacinamide generally non-irritating, suitable even for sensitive skin.

Important Drug interactions

Anticonvulsants (carbamazepine, primidone) — niacinamide may inhibit hepatic metabolism, raising drug levels; theoretical interaction at high doses.
Metformin — chronic high-dose niacinamide may modestly affect glucose homeostasis; minimal clinical relevance at typical supplemental doses.
Statins — no significant interaction documented; niacinamide does not have niacin's HDL-raising lipid effects, so no lipid management interaction.
Pregnancy and lactation — niacinamide is the essential B3 vitamin form; pregnancy RDA is 18 mg/day; supplemental doses up to 500 mg/day generally considered safe but higher doses lack pregnancy-specific safety data.
Children — niacinamide is essential B3; supplementation should match age-appropriate RDA unless under medical direction.

Featured in these supplement guides

Acne→Skin Health & Anti-Aging→

More Hair, Skin & Nails Ingredients

Hair, Skin & Nails
Bovine Collagen
Bovine collagen is hydrolyzed collagen sourced from cow hide, bone, and cartilage — the mo…
Hair, Skin & Nails
Marine Collagen
Marine collagen is hydrolyzed collagen sourced from fish skin and scales — predominantly T…
Hair, Skin & Nails
ceratiq® (Wheat-Derived Phytoceramides — PLT Health)
ceratiq® is PLT Health Solutions' patented, clinically-studied phytoceramide ingredient —…
Hair, Skin & Nails
Tea Tree Oil
Tea tree oil is an essential oil used topically as a natural antiseptic and antimicrobial…

Explore Other Ingredients

Antioxidant
Setria® Glutathione
Setria® is Kyowa Hakko's patented reduced L-glutathione (GSH) produced via fermentation —…
Cardiovascular
CoEnzyme Q10
Coenzyme Q10 (CoQ10) is a lipid-soluble compound essential to mitochondrial ATP production…
Energy
NMN (Nicotinamide Mononucleotide)
NMN (nicotinamide mononucleotide) is a precursor that the body uses to make NAD+, a coenzy…

Frequently asked questions about DermaNiA® (Niacinamide for Skin Health — Sabinsa)

What is DermaNiA?

DermaNiA® is Sabinsa's branded niacinamide (nicotinamide, vitamin B3) for skin health applications. Niacinamide has substantial published evidence for skin applications, primarily via topical use — multiple RCTs document improvements in hyperpigmentation, fine lines, wrinkles, skin barrier function, sebum production, a…

What is DermaNiA used for?

DermaNiA is researched primarily for Hair, Skin & Nails. Ontrac trial (NEJM): 386 patients with history of NMSC randomized to oral niacinamide 500 mg twice daily vs placebo for 12 months.

What is the recommended dosage of DermaNiA?

The clinically studied dose is NMSC prevention (oral): 500 mg twice daily (1,000 mg/day total) — the Chen 2015 Ontrac trial protocol. General skin support (oral): 100-500 mg/day. Always follow the product label and check with a healthcare provider for personal advice.

Is DermaNiA safe, and does it have side effects?

For most healthy adults, DermaNiA is well tolerated at studied doses. Reported effects can include: Excellent tolerability profile at oral doses up to 1,000 mg/day. Does not cause flushing (unlike niacin/nicotinic acid). This is a key distinguishing feature. It may also interact with some medications. DermaNiA is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does DermaNiA interact with any medications?

Possible interactions include: Anticonvulsants (carbamazepine, primidone) — niacinamide may inhibit hepatic metabolism, raising drug levels; theoretical interaction at high doses. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for DermaNiA?

NutraSmarts rates the evidence for DermaNiA as Strong (4 out of 5). It is backed by 2 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention N Engl J Med. 2015;373(17):1618-26. doi: 10.1056/NEJMoa1506197.PubMedUsed to support: Strongest support for the skin-cancer-prevention claim and the main large oral nicotinamide dermatology RCT (ONTRAC): 500 mg twice daily cut new non-melanoma skin cancers in high-risk patients. Honesty: studied oral nicotinamide (the DermaNiA route) but in a high-risk skin-cancer population rather than the general skin-health user, and benefit waned after stopping.
  2. Bissett DL, Oblong JE, Berge CA Niacinamide: A B vitamin that improves aging facial skin appearance Dermatol Surg. 2005;31(7 Pt 2):860-5. doi: 10.1111/j.1524-4725.2005.31732.PubMedUsed to support: Backs the skin-barrier/appearance claim: topical niacinamide improved fine lines, hyperpigmentation, sallowness and skin texture. Honesty: this is topical niacinamide (an industry-conducted split-face study), not oral DermaNiA.
  3. Khodaeiani E, Fouladi RF, Amirnia M, Saeidi M, Karimi ER Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris Int J Dermatol. 2013;52(8):999-1004. doi: 10.1111/ijd.12002.PubMedUsed to support: Backs the acne claim: topical 4% nicotinamide reduced inflammatory acne lesions comparably to topical clindamycin. Honesty: topical niacinamide RCT, not oral DermaNiA, with an active-comparator rather than placebo design.
  4. Navarrete-Solis J, Castanedo-Cazares JP, Torres-Alvarez B, Oros-Ovalle C, Fuentes-Ahumada C, Gonzalez FJ, et al. A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma Dermatol Res Pract. 2011;2011:379173. doi: 10.1155/2011/379173.PubMedUsed to support: Backs the hyperpigmentation/melasma claim: topical 4% niacinamide improved melasma similarly to hydroquinone with fewer side effects. Honesty: small topical niacinamide trial, not oral DermaNiA.